Regeneron (REGN) is a publicly traded Healthcare sector company. As of May 21, 2026, REGN trades at $643.47 with a market cap of $66.02B and a P/E ratio of 15.17. REGN moved +2.94% today. Year to date, REGN is -14.87%; over the trailing twelve months it is +5.69%. Its 52-week range spans $476.49 to $1,070.00. Analyst consensus is strong buy with an average price target of $884.89. Rallies surfaces REGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Itepekimab Cuts Exacerbations 27.1% in AERIFY-1 but Misses in AERIFY-2: Regeneron and Sanofi’s Phase III AERIFY-1 trial showed itepekimab reduced COPD exacerbations by 27.1% (q2w) and 20.5% (q4w), but AERIFY-2 failed to reach statistical significance, with only 1.6% and 12.4% reductions. These conflicting outcomes threaten FDA approval prospects for itepekimab in COPD.
| Metric | Value |
|---|---|
| Price | $643.47 |
| Market Cap | $66.02B |
| P/E Ratio | 15.17 |
| EPS | $42.56 |
| Dividend Yield | 0.94% |
| 52-Week High | $1,070.00 |
| 52-Week Low | $476.49 |
| Volume | 866.13K |
| Avg Volume | 0 |
| Revenue (TTM) | $14.92B |
| Net Income | $4.42B |
| Gross Margin | 0.00% |
19 analysts cover REGN: 0 strong buy, 15 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $884.89.